Cabaletta Bio (CABA) Price & Analysis

Compare

1,228 Followers

CABA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.99 - $5.46

Previous CloseN/A

Volume846.62K

Average Volume (3M)2.18M

Market Cap

$220.43M

Enterprise Value-$75.74M

Total Cash (Recent Filing)$194.68M

Total Debt (Recent Filing)$24.89M

Price to Earnings (P/E)―

Beta4.18

Next Earnings

Nov 12, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.73

Shares Outstanding91,465,230

10 Day Avg. Volume2,327,341

30 Day Avg. Volume2,177,207

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.34

Enterprise Value/Revenue-46.24

Enterprise Value/Gross Profit135.73

Enterprise Value/Ebitda0.55

Forecast

1Y Price Target

$12.00

Price Target Upside321.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Competitive PositioningThe positive feedback has enhanced confidence in rese-cel and, more importantly, Cabaletta's competitive positioning.

Safety And EfficacyEarly safety profile of rese-cel was favorable, with only one Grade 1 CRS (transient fever) and no ICANS reported among patients.

Treatment AdvancementsCabaletta's preconditioning-free approach in pemphigus vulgaris marks a significant advancement in the treatment of autoimmune diseases with CAR T therapy.

Bears Say

Market CompetitionManagement thinks a premium to CAR-Ts for oncology is justified if rese-cel is able to elicit drug-free remissions that are durable for at least two years.

Potential RisksReported events included a transient fever consistent with grade 1 cytokine release syndrome (CRS) in Patient 1 and a disease flare in Patient 2 during the first two weeks post-infusion after stopping immunomodulator that required a course of steroids.

Regulatory ApprovalManagement reiterated its intention to submit a BLA for full approval in myositis in 2027.

Cabaletta Bio News

3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1d ago

IVA

CABA

Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data

13:29 EDT Cabaletta Bio (CABA) jumps 30% to $3.13 after pemphigus vulgaris data Published first on TheFly –...

2d ago

CABA

Cabaletta Bio presents initial dose data from RESET-PV trial of rese-cel

Cabaletta Bio (CABA) presented initial dose data from the RESET-PV trial evaluating rese-cel at 1 x 106 cells/kg...

2d ago

CABA

Promising Potential of Cabaletta Bio’s Rese-cel Therapy Drives Buy Rating

Analyst Michael Ulz of Morgan Stanley reiterated a Buy rating on Cabaletta Bio, retaining the price target of...

1d ago

CABA

Promising Early Data from Cabaletta Bio’s Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment

Analyst Samantha Semenkow of Citi maintained a Buy rating on Cabaletta Bio, retaining the price target of $10.00....

1d ago

CABA

Cabaletta Bio Presents Promising RESET-PV Trial Data

Cabaletta Bio ( ($CABA) ) has shared an announcement. On October 9, 2025, Cabaletta Bio presented new clinical...

2d ago

CABA

Cabaletta Bio: Buy Rating Backed by Promising Trial Data and Strategic Financial Outlook

William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating on...

22d ago

CABA

Cabaletta Bio Updates on Rese-cel Therapy Progress

Cabaletta Bio ( ($CABA) ) has shared an announcement. On September 3, 2025, Cabaletta Bio announced an updated...

1M ago

CABA

Cabaletta Bio price target lowered to $16 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Cabaletta Bio (CABA) to $16 from $25 and keeps a...

2M ago

CABA

Cabaletta Bio price target lowered to $2 from $3 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Cabaletta Bio (CABA) to $2 from $3...

2M ago

CABA

Cabaletta Bio Reports Progress in Clinical Trials

Cabaletta Bio, Inc. ( ($CABA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

CABA

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on CABA stock, giving a Buy rating today....

2M ago

CABA

Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MG is a Phase 1/2 open-label...

2M ago

CABA

Cabaletta Bio files $240M mixed securities shelf

08:27 EDT Cabaletta Bio (CABA) files $240M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

CABA

CABA FAQ

What was Cabaletta Bio’s price range in the past 12 months?

Cabaletta Bio lowest stock price was $0.98 and its highest was $5.46 in the past 12 months.

What is Cabaletta Bio’s market cap?

Cabaletta Bio’s market cap is $220.43M.

When is Cabaletta Bio’s upcoming earnings report date?

Cabaletta Bio’s upcoming earnings report date is Nov 12, 2025 which is in 32 days.

How were Cabaletta Bio’s earnings last quarter?

Cabaletta Bio released its earnings results on Aug 07, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.08.

Is Cabaletta Bio overvalued?

According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cabaletta Bio pay dividends?

Cabaletta Bio does not currently pay dividends.

What is Cabaletta Bio’s EPS estimate?

Cabaletta Bio’s EPS estimate is -0.47.

How many shares outstanding does Cabaletta Bio have?

Cabaletta Bio has 91,465,230 shares outstanding.

What happened to Cabaletta Bio’s price movement after its last earnings report?

Cabaletta Bio reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cabaletta Bio?

Currently, no hedge funds are holding shares in CABA

Cabaletta Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-76.34%

Trailing 12-Months

Asset Growth

3.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cabaletta Bio

Cabaletta Bio (CABA) is a biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's core product pipeline involves utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) T cell technology to target and eliminate disease-causing B cells while preserving healthy B cells, aiming to provide a transformative impact on patients' lives.

Cabaletta Bio (CABA) Earnings & Revenues

Historic Earnings Reports

CABA Stock 12 Month Forecast

Average Price Target

$12.00

▲(321.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","23":"$23","5.75":"$5.75","11.5":"$11.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.75,11.5,17.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,3.8246153846153845,5.3392307692307694,6.853846153846154,8.368461538461538,9.883076923076924,11.397692307692308,12.912307692307694,14.426923076923078,15.941538461538462,17.456153846153846,18.970769230769232,20.485384615384614,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,3.0553846153846154,3.8007692307692307,4.546153846153846,5.291538461538462,6.036923076923077,6.7823076923076915,7.527692307692307,8.273076923076923,9.018461538461539,9.763846153846153,10.509230769230768,11.254615384615384,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,2.286153846153846,2.2623076923076924,2.2384615384615385,2.2146153846153847,2.190769230769231,2.166923076923077,2.143076923076923,2.1192307692307693,2.0953846153846154,2.0715384615384616,2.0476923076923077,2.023846153846154,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >